Overview


According to FutureWise analysis the market for Antihyperlipidemic Drugs in 2023 is US$ 12.76 billion, and is expected to reach US$ 20.83 billion by 2031 at a CAGR of 6.30%.

Antihyperlipidemic drugs are medications that help reduce the cholesterol levels. It also helps improve the cholesterol levels. Antihyperlipidemic drugs also lower serum levels of cholesterol and different lipids. They are also known as lipid-lowering agents; these drugs provide adequate treatment for hyperlipidemia (increased lipid level in the blood). The prevalence of coronary artery disease (CAD) is the most common cause of death among adults and is higher in individuals with hyperlipidemia. High level of lipids and triglyceride is associated with metabolic syndrome consisting of insulin resistance, abdominal obesity, hypertension, and proinflammatory and prothrombotic states.

There are different types of antihyperlipidemic drugs, which include bile acid sequesters, cholesterol absorption inhibitors, PCSK9 inhibitors, fibrates, miscellaneous (antihyperlipidemic agents), and statins. Bile acid sequestrants are a cholesterol-lowering drug that works inside the intestine by attaching to bile, a greenish fluid produced by the liver containing cholesterol that helps in food digestion. The binding process means that less cholesterol is available in the body. Resins lower LDL cholesterol and give a slight boost to HDL cholesterol levels. In addition, PCSK9 inhibitors attach to a specific protein on the surface of liver cells, which results in lowered LDL ("bad") cholesterol. This can be taken as the class of drug with statins. Also, Statins are one of the better-known types of cholesterol-lowering drugs. Healthcare experts choose these for most individuals because they work well and are considered first-line treatment for most individuals with high cholesterol.

FutureWise Market Research has published a report that provides an insightful analysis antihyperlipidemic drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antihyperlipidemic drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • AstraZeneca plc
  • Grifols S.A
  • Pfizer, Inc
  • Shire Plc
  • Biotest AG
  • Octapharma AG
  • Kedrion S.P.A.
  • Baxalta Incorporated
  • Talecris Biotherapeutics, Inc
  • Boehringer Ingelheim GmbH
  • Merck KGaA
  • Johnson and Johnson
  • Bayer AG
  • Takeda Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company
  • Sanofi S.A
  • Novartis International AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antihyperlipidemic Drugs Market:

  • In February 2022, Amgen and BieGene announced an alliance to develop and commercialize BieGene's investigational PCSK9 inhibitor in China. The drug is presently in phase 2 development and is being evaluated for the treatment of hyperlipidemia.
     
  • In January 2022, Ionis Pharmaceuticals and Novartis announced a collaboration to develop RNA-targeted therapeutics for the treatment of cardiovascular diseases, including hyperlipidemia.

The rising prevalence of the aging population worldwide is expected to drive the demand for antihyperlipidemic drugs. As individuals age, the inclination for high cholesterol levels and related cardiovascular diseases rises significantly. This demographic shift towards older individuals creates a significant market for antihyperlipidemic drugs, compelling more extended and innovative pharmaceutical solutions to serve the unique healthcare needs of this aging population. Moreover, the rise in hyperlipidemia cases attributed to modern lifestyles marked by long periods of inactivity, poor dietary choices, and increasing rates of obesity. Sedentary habits related to a prevalence of calorie-dense, nutrient-deficient diets have become prevalent, leading to a rise in high cholesterol levels and related health issues. This prevailing trend, aggravated by the ongoing rise in obesity rates, is anticipated to continue, thus driving the global need for antihyperlipidemic drugs as a vital component of healthcare strategies. Also, ongoing R&D efforts within the pharmaceutical industry and research institutions are delivering a new generation of antihyperlipidemic drugs with upgraded efficacy and improved safety profiles. Advancements in drug formulations, mechanisms of action, and targeted delivery systems are reengineering treatment options for hyperlipidemia. With the introduction of these innovative pharmaceuticals, the potential customer base for antihyperlipidemic drugs is expected to drive the market significantly. However, the adverse side effects, such as nausea, constipation, headaches, and other, poses significant restraints on the market growth. These side effects may lead to patient discomfort and hesitation to adhere to prescribed medications, ultimately hindering treatment efficiency. Therefore, hampering the growth of the market over the forecast period.
 

By Class

  • Bile Acid Sequesters
  • Cholesterol Absorption Inhibitors
  • Fibrates (Fibric Acid Derivatives)
  • Miscellaneous Antihyperlipidemic Agents
  • PCSK9 Inhibitors
  • Statins

By Distribution Channels

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to factors like increasing demand for antihyperlipidemic drugs, a large patient population, growing cardiovascular disease, a high level of awareness about cardiovascular health, well-established healthcare infrastructure, substantial investments in R&D, and favorable reimbursement scenarios are fueling the market in the region. Moreover, the surge in sedentary lifestyle, increase in the geriatric population, the rise in the obese population, the demand for satin antihyperlipidemic drugs, the approval of new and advanced drugs, and the presence of key players in the area are expected to boost the growth of the antihyperlipidemic drugs market over the projection period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antihyperlipidemic Drugs Market By Class, By Distribution Channels and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antihyperlipidemic Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Class Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antihyperlipidemic Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antihyperlipidemic Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Class Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Class Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antihyperlipidemic Drugs Market, By Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Bile Acid Sequesters
        2. Cholesterol Absorption Inhibitors
        3. Fibrates (Fibric Acid Derivatives)
        4. Miscellaneous Antihyperlipidemic Agents
        5. PCSK9 Inhibitors
        6. Statins

  • 8.   Antihyperlipidemic Drugs Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Stores
        3. Online Retailers

  • 9.   North America Antihyperlipidemic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antihyperlipidemic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antihyperlipidemic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antihyperlipidemic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca plc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Grifols S.A
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer, Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Shire Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Biotest AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Octapharma AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Kedrion S.P.A.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Baxalta Incorporated
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Talecris Biotherapeutics, Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Boehringer Ingelheim GmbH
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Merck KGaA
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12.Johnson and Johnson
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13.Bayer AG
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14.Takeda Pharmaceutical Co., Ltd.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15.Daiichi Sankyo Company
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16.Sanofi S.A
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17.Novartis International AG
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients